TY - ABST
T1 - EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice
AU - Mandl, Peter
AU - D'Agostino, Maria Antonietta
AU - Navarro-Compán, Victoria
AU - Geßl, Irina
AU - Sakellariou, Garifallia
AU - Abhishek, Abhishek
AU - Becce, Fabio
AU - Dalbeth, Nicola
AU - Ea, Hang-Korng
AU - Filippucci, Emilio
AU - Hammer, Hilde Berner
AU - Iagnocco, Annamaria
AU - de Thurah, Annette
AU - Naredo, Esperanza
AU - Ottaviani, Sebastien
AU - Pascart, Tristan
AU - Pérez-Ruiz, Fernando
AU - Pitsillidou, Irene A
AU - Proft, Fabian
AU - Rech, Juergen
AU - Schmidt, Wolfgang A
AU - Sconfienza, Luca Maria
AU - Terslev, Lene
AU - Wildner, Brigitte
AU - Zufferey, Pascal
AU - Filippou, Georgios
N1 - COPECARE
PY - 2023
Y1 - 2023
N2 - OBJECTIVE: To formulate evidence-based recommendations and overarching principles on the use of imaging in the clinical management of crystal-induced arthropathies (CiAs).METHODS: An international task force of 25 rheumatologists, radiologists, methodologists, healthcare professionals and patient research partners from 11 countries was formed according to the EULAR standard operating procedures. Fourteen key questions on the role of imaging in the most common forms of CiA were generated. The CiA assessed included gout, calcium pyrophosphate deposition disease and basic calcium phosphate deposition disease. Imaging modalities included conventional radiography, ultrasound, CT and MRI. Experts applied research evidence obtained from four systematic literature reviews using MEDLINE, EMBASE and CENTRAL. Task force members provided level of agreement (LoA) anonymously by using a Numerical Rating Scale from 0 to 10.RESULTS: Five overarching principles and 10 recommendations were developed encompassing the role of imaging in various aspects of patient management: making a diagnosis of CiA, monitoring inflammation and damage, predicting outcome, response to treatment, guided interventions and patient education. Overall, the LoA for the recommendations was high (8.46-9.92).CONCLUSIONS: These are the first recommendations that encompass the major forms of CiA and guide the use of common imaging modalities in this disease group in clinical practice.
AB - OBJECTIVE: To formulate evidence-based recommendations and overarching principles on the use of imaging in the clinical management of crystal-induced arthropathies (CiAs).METHODS: An international task force of 25 rheumatologists, radiologists, methodologists, healthcare professionals and patient research partners from 11 countries was formed according to the EULAR standard operating procedures. Fourteen key questions on the role of imaging in the most common forms of CiA were generated. The CiA assessed included gout, calcium pyrophosphate deposition disease and basic calcium phosphate deposition disease. Imaging modalities included conventional radiography, ultrasound, CT and MRI. Experts applied research evidence obtained from four systematic literature reviews using MEDLINE, EMBASE and CENTRAL. Task force members provided level of agreement (LoA) anonymously by using a Numerical Rating Scale from 0 to 10.RESULTS: Five overarching principles and 10 recommendations were developed encompassing the role of imaging in various aspects of patient management: making a diagnosis of CiA, monitoring inflammation and damage, predicting outcome, response to treatment, guided interventions and patient education. Overall, the LoA for the recommendations was high (8.46-9.92).CONCLUSIONS: These are the first recommendations that encompass the major forms of CiA and guide the use of common imaging modalities in this disease group in clinical practice.
KW - Chondrocalcinosis/diagnostic imaging
KW - Crystal Arthropathies/diagnostic imaging
KW - Evidence-Based Medicine
KW - Gout/diagnostic imaging
KW - Humans
KW - Magnetic Resonance Imaging/methods
KW - Radiography
KW - Tomography, X-Ray Computed
KW - Ultrasonography/methods
KW - Magnetic Resonance Imaging
KW - Ultrasonography
KW - Crystal arthropathies
M3 - Conference abstract for conference
SP - Arthritis Rheumatology 75 (suppl 9
T2 - ACR Convergence 2023
Y2 - 10 November 2023 through 15 November 2023
ER -